Accéder au contenu
Merck
  • CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.

CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.

Oncotarget (2017-12-08)
Runzhou Zhuang, Di Lu, Jianyong Zhuo, Xuanyu Zhang, Kun Wang, Xuyong Wei, Qiang Wei, Wei Wang, Haiyang Xie, Lin Zhou, Xiao Xu, Shusen Zheng
RÉSUMÉ

CR6-interacting factor 1 (CRIF1) regulates cell cycle progression and the DNA damage response. Here, we show that CRIF1 expression is decreased in hepatocellular carcinoma (HCC) tissues and positively correlates with patients' survival.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
MISSION® esiRNA, targeting human CHN1
Sigma-Aldrich
MISSION® esiRNA, targeting human GADD45GIP1